Evonik and InVitria form strategic partnership to supply animal-free albumin to global biopharma market
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
Consolidated revenue from operations stood at Rs. 111.05 crore
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
Total income for the period stood at Rs. 7101.28 crore
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
Diversifying its portfolio to include late-phase antiviral agent
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
Subscribe To Our Newsletter & Stay Updated